Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Bone is the most common site of metastases in prostate cancer and bone complications cause
substantial morbidity to this population. Phase III studies have shown that zoledronic acid
is effective in decreasing the morbidity associated with bone metastases. Zoledronic acid
(ZA) is generally well tolerated but may have side effects such as hypocalcemia, renal
impairment and osteonecrosis of the jaw. Administration of ZA as infrequently as once yearly
is sufficient to prevent osteopenia or osteoporosis. The optimal treatment interval is
unknown, but the drug is often empirically administered every 3-4 weeks. The cost of such
treatment is high, and the risk of exposing patients (especially those at low risk) to
potential serious side effects with uncertain benefit warrants investigation. This study will
determine the duration of suppression of bone turnover in prostate cancer patients with bone
metastases following a single infusion of Zoledronic Acid and its effect on quality of life.